2018 Eosinophilic Esophagitis Drug Development- Pipeline Analysis Report

  • ID: 4527596
  • Report
  • 45 pages
  • VPA Research
1 of 4

FEATURED COMPANIES

  • Acorda Therapeutics Inc
  • ChemomAb Ltd
  • DURECT Corp
  • Noxopharm Ltd
  • PharmAkea Therapeutics
  • Shire Plc
  • MORE
Eosinophilic Esophagitis (EoE) represents the allergic inflammation of the esophagus that is caused by antigens in both children and adults. It is characterized by esophageal dysfunction and eosinophil infiltration. With increasing incidence and prevalence of the disease, research activities focusing on understanding the disease and development of treatment options are increasing significantly.

Around 15 companies and universities are focusing on developing treatment options for Eosinophilic Esophagitis.

To assist investigators and funding and regulatory organizations, the publisher has come up with a comprehensive report on Eosinophilic Esophagitis pipeline. The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.

Current status, developmental phase, participating companies and entities, recent developments, orphan drug/ fast track/ other designations, drug class are provided for each Eosinophilic Esophagitis pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.

In addition to complete details of each product, the report provides key trends in Eosinophilic Esophagitis pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Acorda Therapeutics Inc
  • ChemomAb Ltd
  • DURECT Corp
  • Noxopharm Ltd
  • PharmAkea Therapeutics
  • Shire Plc
  • MORE
1.1 List of Figures
1.2 List of Tables

2 Eosinophilic Esophagitis Pipeline Analysis
2.1 Disease and Pipeline Overview
2.2 Eosinophilic Esophagitis Pipeline Snapshot
2.3 Eosinophilic Esophagitis Pipeline by Phase
2.4 Eosinophilic Esophagitis Pipeline by Company
2.5 Eosinophilic Esophagitis Pipeline by Mechanism of Action

3 Eosinophilic Esophagitis- Company Wise Pipeline Analysis
  • Adare Pharmaceuticals
  • Biotica Pharmaceuticals
  • Celgene Corp
  • DBV Technologies
  • Dr Falk Pharma
  • Glycan Biosciences
  • Quorum Innovations LLC
  • Sanofi
  • Shire Plc
4 Eosinophilic Esophagitis R&D Pipeline Snapshots
  • Drug wise Pipeline Details
  • Therapeutic Candidate Name
  • Originator
  • Co-Developer/ License Partner
  • Orphan Drug Designation
  • Development Phase
  • Mechanism of Action
  • Current Status
  • Ongoing Clinical Trial Details
5 Recent Developments in Eosinophilic Esophagitis Pipeline

6 Appendix
6.1 About the Publisher
6.2 Sources and Research Methodology

1.1 List of Figures
Figure 1: Eosinophilic Esophagitis Pipeline by Phase, H1- 2018
Figure 2: Eosinophilic Esophagitis Pipeline by Companies, H1- 2018
Figure 3: Company Wise Pipeline Drug Phases, H1- 2018
Figure 4: Eosinophilic Esophagitis Pipeline by Mechanism of Action, H1- 2018
Figure 5: Mechanism Wise Pipeline Drug Phases, H1- 2018

1.2 List of Tables
Table 1: Eosinophilic Esophagitis Pipeline by Phase, H1- 2018
Table 2: Eosinophilic Esophagitis Pipeline by Companies, H1- 2018
Table 3: Eosinophilic Esophagitis Pipeline by Mechanism of Action, H1- 2018
Table 4: Adare Pharmaceuticals Eosinophilic Esophagitis Pipeline, May 2018
Table 5: Biotica Pharmaceuticals Eosinophilic Esophagitis Pipeline, May 2018
Table 6: Celgene Corp Eosinophilic Esophagitis Pipeline, May 2018
Table 7: DBV Technologies Eosinophilic Esophagitis Pipeline, May 2018
Table 8: Dr Falk Pharma Eosinophilic Esophagitis Pipeline, May 2018
Table 9: Glycan Biosciences Eosinophilic Esophagitis Pipeline, May 2018
Table 10: Quorum Innovations LLC Eosinophilic Esophagitis Pipeline, May 2018
Table 11: Sanofi Eosinophilic Esophagitis Pipeline, May 2018
Table 12: Shire Plc Eosinophilic Esophagitis Pipeline, May 2018
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Acorda Therapeutics Inc
  • Albireo Pharma Inc
  • ChemomAb Ltd
  • Conatus Pharmaceuticals Inc
  • Dr. Falk Pharma GmbH
  • DURECT Corp
  • Gilead Sciences
  • HighTide Biopharmaceutical
  • Immune Pharmaceuticals Inc
  • Intercept Pharmaceuticals Inc
  • NGM Biopharmaceuticals Inc
  • Noxopharm Ltd
  • Orbsen Therapeutics Ltd
  • PharmAkea Therapeutics
  • Sancilio & Company Inc
  • Shire Plc
  • Tobira Therapeutics
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll